NASDAQ · SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH · LARGE CAP
Medpace Holdings, Inc. MEDP
11 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$2.5B
▲ 20.0% vs FY2024
EPS · FY25
$15.28
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
70.2%
Net margin · FY25
17.8%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 2.5B
Revenue, FY2025 · full 11-year series below
Revenue
Net income
18 cents of every revenue dollar became profit this year.
Per share
USD 15.28
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
70.2%
Return on equity, FY2025
ROE
Operating margin21.1%
Net margin17.8%
Return on assets22.1%
Each USD of equity produced 70 cents of profit this year.
Returned to shareholders
USD 860.4M
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacksUSD 860.4M
Share of profit190.7%
Consecutive raises—
USD 860.4M in buybacks — 191% of the year's profit, so the payout drew on cash built up earlier.
Growth
+22.3% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+20.1%
+22.3%
+21.6%
Net income
+22.5%
+25.4%
EPS, diluted
+28.0%
+31.8%
Returned to shareholders
+1.4%
+59.9%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.03B
Shares outstanding, FY2025
Change, 5 years−20.1%
Change, 10 years−13.0%
The share count shrank 20% in five years — the same company, cut into fewer, larger slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 2.0B
total assets, end of FY2025
Total assetsUSD 2.0B
EquityUSD 459.1M
CashUSD 497.0M
Current ratio0.74×
Equity funds 23% of total assets.
History
11 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
Revenue $B
2.5
2.1
1.9
1.5
1.1
0.9
0.9
0.7
0.4
0.4
0.4
Operating income $B
0.5
0.4
0.3
0.3
0.2
0.2
0.1
0.1
0.1
0.1
0.0
EBITDA $B
0.6
0.5
0.4
0.3
0.2
0.2
0.1
0.1
0.1
0.1
0.0
Income tax $B
0.1
0.1
0.1
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Net income $B
0.5
0.4
0.3
0.2
0.2
0.1
0.1
0.1
0.0
0.0
−0.0
EPS, diluted $
15.28
12.63
8.88
7.28
4.81
3.84
2.67
1.97
0.98
0.37
−0.28
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
ROE %
70.2
58.4
59.8
36.6
20.7
19.0
15.2
13.2
7.0
2.6
−2.1
Shares out B
0.03
0.03
0.03
0.03
0.04
0.04
0.04
0.04
0.04
0.04
0.03
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
33 of 33
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed